Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calpurbatug in Prosthetic Joint Infection
NCT04763759Phase 1Completed
- Sponsor
- Trellis Bioscience
- Start
- Feb 2021
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of calpurbatug in prosthetic joint infection (PJI) (3 cohorts), sponsored by Trellis Bioscience. Primary endpoints: Incidence of Abnormal Physical Examination Findings at 16 weeks, Incidence of Abnormal Serum Chemistries and Hematology at 16 weeks and 1 more. Started Feb 2021; status: completed.
02
Drugs
calpurbatug
03
Conditions
prosthetic joint infection (PJI)
Beyond the preview
Go deeper on NCT04763759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04763759.